embecta.com - EMBC Company Value to Revenue Ratio

Public company logo of Embecta (EMBC)

Embecta Corp. (EMBC) leads the insulin systems segment, leveraging the rise in diabetes and the launch of patch pumps. The company's valuation-to-revenue trajectory illustrates the market reaction, where the 1598.66 mark serves as a current indicator. The spin-off from BD attracts talent through a high-quality corporate culture and RSUs. However, a narrow needle production profile necessitates the implementation of digital IT services for diversification.

EMBC Embecta Corp.: EV/Sales Multiple in the range 11/23/2025 - 11/19/2026

EMBC (Embecta Inc.): analytical breakdowns and indicator data

Fundamental valuation:Embecta Corp. EMBC
Mass-produced product of Embecta Corp

To isolate fundamental resilience from market noise, capital requires an analysis of business value excluding debt load. This indicator measures the enterprise value relative to generated revenue, eliminating the influence of borrowing structures. The trend of the enterprise value-to-revenue ratio allows for an assessment of whether current quotes are fair. For Embecta Corp. (EMBC), such a metric is supported by high barriers to entry and strict FDA control, which guarantees stable cash flows during production scaling.

Competitor analysis for Embecta Corp.

BSX (Boston Scientific) - Company Value to Revenue Ratio|EW: EV/Sales Multiple|RMD - Total Company Value-to-Revenue Ratio|PODD (Insulet Inc.) - EV/Sales Multiple|Company Value to Revenue Zimmer Biomet Corp (ZBH)|EV/Sales Multiple COO|Company Value to Revenue Align Technology, Inc. ALGN|EV/Sales Multiple GMED (globusmedical.com)|EV/Sales Multiple TransMedics Group, Inc. TMDX|ATEC - Enterprise Value-to-Revenue Ratio|AORT: Enterprise Value-to-Revenue Ratio|ENOV (Enovis Corporation) - Company Value to Revenue|Integra LifeSciences - Business Value to Revenue|ESTA (Establishment Labs Inc) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Beta Bionics, Inc. BBNX|Enterprise Value-to-Revenue Ratio IRADIMED Corp (IRMD)|Tandem Diabetes Care (TNDM) - Enterprise Value-to-Sales Ratio|Axogen Surgical - Company Value to Revenue|EV/Sales Multiple SI-BONE, Inc. SIBN|Orthofix Medical - EV/Sales Multiple|Enterprise Value to Sales Volume BVS|OrthoPediatrics (KIDS) - Enterprise Value-to-Revenue Ratio|Enterprise Value to Sales Volume TMCI (Treace Corp)|Enterprise Value-to-Revenue Ratio blade.com|Company Value to Revenue Carlsmed Inc (CARL)|EV/Sales Multiple RXST|CLPT - Enterprise Value-to-Revenue Multiple|Enterprise Value-to-Revenue Ratio Stereotaxis, Inc. STXS|STIM: Company Value to Revenue Ratio|SGHT: Company Value to Revenue|Orchestra BioMed Inc. - Enterprise Value-to-Revenue Coefficient|ANIK: EV/Sales Multiple|NSPR - Total Company Value-to-Revenue Ratio|ZJYL (Jin Medical) - EV/Sales Multiple|Vivani Medical (VANI) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple XTNT|EV/Sales Multiple n1mtc.com (NMTC)|Modular Medical Inc - Company Value to Revenue|Myomo, Inc (MYO) - Enterprise Value-to-Revenue Multiple|COCH: Company Value to Revenue|Total Company Value-to-Revenue Ratio Vivos Therapeutics VVOS|enVVeno Medical Corp. (NVNO) - Enterprise Value-to-Revenue Ratio|Sintx Technologies - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Tenon Medical Inc.|LFWD: Business Value to Revenue|EV/Sales Multiple AMIX|Enterprise Value-to-Revenue Coefficient IVF|Enterprise Value-to-Revenue Ratio Bone Biologics BBLG|Total Company Value-to-Revenue Ratio axonics.com (AXNX)|BIOL - Enterprise Value-to-Revenue Ratio|Dynatronics (DYNT) - Company Value to Revenue|Paragon 28, Inc. (FNA) - Enterprise Value-to-Revenue Ratio|INVO - Total Company Value-to-Revenue Ratio